

Financial news for PRQR dated on 2020-04-01: 77 Biggest Movers From Yesterday

Financial news for PRQR dated on 2020-03-31: ProQR Therapeutics Filing Shows Registration For \$75M Common Stock Offering

Financial news for PRQR dated on 2020-03-31: Afternoon Market Stats in 5 Minutes

Financial news for PRQR dated on 2020-03-31: 56 Stocks Moving In Tuesday's Mid-Day Session

Financial news for PRQR dated on 2020-03-31: ProQR Reports Findings From Three-Month Interim Analysis Of Phase 1/2 Steller Trial Of QR-421a In Adults With Usher Syndrom And nsRP

Financial news for PRQR dated on 2020-03-29: The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty

Financial news for PRQR dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for PRQR dated on 2020-03-03: 108 Biggest Movers From Yesterday

Financial news for PRQR dated on 2020-02-26: 24 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for PRQR dated on 2020-02-26: ProQR Q4 EPS EUR0.39

Financial news for PRQR dated on 2020-01-30: ProQR Therapeutics Reports Receives Rare Pediatric Disease Designation For QR-421a

Financial news for PRQR dated on 2019-12-18: 26 Stocks Moving in Wednesday's Pre-Market Session

Financial news for PRQR dated on 2019-12-17: 74 Biggest Movers From Yesterday

Financial news for PRQR dated on 2019-12-16: 40 Stocks Moving In Monday's Mid-Day Session

Financial news for PRQR dated on 2019-12-11: ProQR Announces First Patient Dosed In Phase 1/2 Aurora Trial Of QR-1123 For Autosomal Dominant Retinitis Pigmentosa

Financial news for PRQR dated on 2019-12-02: 52 Biggest Movers From Friday

Financial news for PRQR dated on 2019-11-21: ProQR Therapeutics Reports Received Orphan Drug Designation For QR-1123 For Autosomal Dominant Retinitis Pigmentosa

Financial news for PRQR dated on 2019-11-21: 63 Biggest Movers From Yesterday

Financial news for PRQR dated on 2019-11-19: Citi Maintains Buy on ProQR Therapeutics, Lowers Price Target to \$33

Financial news for PRQR dated on 2019-11-06: ProQR Therapeutics Q3 EPS EUR(0.31) Down From EUR(0.18) YoY

Financial news for PRQR dated on 2019-10-22: 38 Biggest Movers From Yesterday

Financial news for PRQR dated on 2019-10-18: 32 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for PRQR dated on 2019-10-18: ProQR Reports Closing Of 9.09M Share Common Stock Offering At \$5.50/Share For Gross Proceeds ~\$57.5M

Financial news for PRQR dated on 2019-10-16: Stocks That Hit 52-Week Lows On Wednesday

Financial news for PRQR dated on 2019-10-16: 17 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for PRQR dated on 2019-10-16: 23 Stocks Moving in Wednesday's Pre-Market Session

Financial news for PRQR dated on 2019-10-16: The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch

Financial news for PRQR dated on 2019-10-16: ProQR Therapeutics 6-K Shows Cash, Cash Equivalents Of EUR74.8M As Of Sep. 30, 2019

Financial news for PRQR dated on 2019-10-16: ProQR Prices 9.09M Share Underwritten

Public Offering of Ordinary Shares @\$5.50/Share

Financial news for PRQR dated on 2019-10-15: ProQR Therapeutics shares are trading lower after the company announced a \$50 million common stock offering.

Financial news for PRQR dated on 2019-10-15: ProQR Reports \$50M Common Stock Offering

Financial news for PRQR dated on 2019-10-15: ProQR Receives Rare Pediatric Disease Designation From FDA For Sepofarsen For The Treatment Of LCA10

Financial news for PRQR dated on 2019-10-10: ProQR Shares Fall To Session Low, Down 2.9%, Despite Traders Circulating JMP Comments Suggesting Positive Data For Sepofarsen Bodes Well For LCA10 Trial; Firm Reiterates Market Outperform, \$25 Price Target

Financial news for PRQR dated on 2019-10-10: 5 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for PRQR dated on 2019-10-10: The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO

Financial news for PRQR dated on 2019-10-10: ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients

Financial news for PRQR dated on 2019-10-09: 28 Stocks Moving In Wednesday's Mid-Day Session

Financial news for PRQR dated on 2019-10-09: Mid-Day Market Update: Crude Oil Up 1%; James River Group Shares Plunge

Financial news for PRQR dated on 2019-10-09: Mid-Morning Market Update: Markets Open Higher; Johnson & Johnson Hit With \$8B Verdict In Risperdal Lawsuit

Financial news for PRQR dated on 2019-10-01: The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines

Financial news for PRQR dated on 2019-09-30: Stocks That Hit 52-Week Lows On Monday

Financial news for PRQR dated on 2019-09-25: The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug

Financial news for PRQR dated on 2019-09-24: The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger

Financial news for PRQR dated on 2019-09-23: Stocks That Hit 52-Week Lows On Monday

Financial news for PRQR dated on 2019-09-09: ProQR Recieves Fast Track Designation from the FDA for QR-1123

Financial news for PRQR dated on 2019-09-04: The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books

Financial news for PRQR dated on 2019-08-29: The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings

Financial news for PRQR dated on 2019-08-12: ProQR Reports Clearance Of Investigational New Drug to Start Trial Of QR-1123 In Patients With Autosomal Dominant Retinitis Pigmentosa

Financial news for PRQR dated on 2019-08-07: ProQR Therapeutics Q2 EPS EUR(0.30) Down From EUR(0.23) YoY

Financial news for PRQR dated on 2019-07-29: ProQR Therapeutics shares are trading higher after the company's sepofarsen (QR-110) drug candidate was granted access to the PRiority Medicines (PRIME) program by the European Medicines Agency (EMA).

Financial news for PRQR dated on 2019-07-29: European Medicines Agency Grants PRIME Access To ProQR's Sepofarsen For Leber's Congenital Amaurosis 10

Financial news for PRQR dated on 2019-07-15: 40 Biggest Movers From Friday

Financial news for PRQR dated on 2019-07-12: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for PRQR dated on 2019-07-12: 55 Biggest Movers From Yesterday

Financial news for PRQR dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for PRQR dated on 2019-07-02: ProQR Highlights Presentation On QR-421a Program In Ophthalmology At Usher Syndrome Coalition Conference In July

Financial news for PRQR dated on 2019-05-08: ProQR Therapeutics Q1 EPS \$(0.36) Beats \$(0.41) Estimate

Financial news for PRQR dated on 2019-05-08: ProQR Therapeutics N.V. - Ordinary Shares Q1 EPS EUR(0.36) vs EUR(0.33) In Same Qtr. Last Year

Financial news for PRQR dated on 2019-04-23: Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'

Financial news for PRQR dated on 2019-04-15: ProQR Expects Data From its Phase 2/3 ILLUMINATE Trial at Year End 2020

Financial news for PRQR dated on 2019-04-15: ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10

Financial news for PRQR dated on 2019-03-26: ProQR Therapeutics Says it Will Spin Out its Dystrophic Epidermolysis Bullosa Business INTO a Newly Formed Company

Financial news for PRQR dated on 2019-03-11: ProQR Doses First Patient In Phase 1/2 STELLAR Trial Of QR-421a For Usher Syndrome Type 2

Financial news for PRQR dated on 2019-02-27: ProQR Q4 EPS EUR(0.33) Up From EUR(0.39) YoY

Financial news for PRQR dated on 2019-02-20: 71 Biggest Movers From Yesterday

Financial news for PRQR dated on 2019-02-06: 50 Biggest Movers From Yesterday

Financial news for PRQR dated on 2019-01-11: 55 Biggest Movers From Yesterday

Financial news for PRQR dated on 2019-01-10: 40 Stocks Moving In Thursday's Mid-Day Session

Financial news for PRQR dated on 2019-01-07: ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber's Congenital Amaurosis 10

Financial news for PRQR dated on 2019-01-03: 66 Biggest Movers From Yesterday

Financial news for PRQR dated on 2019-01-02: 45 Stocks Moving In Wednesday's Mid-Day Session

Financial news for PRQR dated on 2019-01-02: ProQR Therapeutics shares are trading higher after the company received Fast Track Destination from the FDA for QR-421a.

Financial news for PRQR dated on 2019-01-02: 16 Stocks Moving In Wednesday's Pre-Market Session

Financial news for PRQR dated on 2019-01-02: A Peek Into The Markets: US Stock Futures Tumble

Financial news for PRQR dated on 2019-01-02: ProQR Receives Fast Track Designation From FDA For QR-421a For Usher Syndrome Type 2

Financial news for PRQR dated on 2018-12-23: The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results

Financial news for PRQR dated on 2018-12-17: UPDATE: ProQR Says Phase 1/2 PQ-110-001 Study Of QR-110 Will Be Completed, In Parallel With Phase 2/3 ILLUMINATE Study, Expected To Be Initiated In 1H'19

Financial news for PRQR dated on 2018-12-17: ProQR Issues Release Highlighting Publication Of Previously-Published QR-110 Data For Leber's Congenital Amaurosis 10 In 'Nature Medicine'

Financial news for PRQR dated on 2018-12-10: ProQR Wins a EUR 4.7M Innovation Credit From the Dutch Government

Financial news for PRQR dated on 2018-12-04: ProQR Announces Clearance Of IND To Start Clinical Trial Of QR-421a In Usher Syndrome Type 2 Patients

Financial news for PRQR dated on 2018-11-14: Benzinga's Top Upgrades, Downgrades For November 14, 2018

Financial news for PRQR dated on 2018-11-14: Cantor Fitzgerald Initiates Coverage On ProQR Therapeutics with Overweight Rating, Announces \$40 Price Target

Financial news for PRQR dated on 2018-11-07: ProQR Therapeutics Filing Shows Registration For \$300M Mixed Securities Offering

Financial news for PRQR dated on 2018-11-06: Stocks Which Set New 52-Week High Yesterday, Mon., Nov. 5, 2018

Financial news for PRQR dated on 2018-11-02: 76 Biggest Movers From Yesterday

Financial news for PRQR dated on 2018-10-29: UPDATE: ProQR Granted Exclusive Global License To QR-1123, Relevant Patents For Upfront Payment Of \$2.5M At \$22.23/Share

Financial news for PRQR dated on 2018-10-29: ProQR Therapeutics Reports In-Licenses Global Rights To Ophthalmology Drug Candidate From Ionis Pharma

Financial news for PRQR dated on 2018-09-19: Benzinga's Top Upgrades, Downgrades For September 19, 2018

Financial news for PRQR dated on 2018-09-19: Evercore ISI Group Initiates Coverage On ProQR Therapeutics with Outperform Rating, Announces \$35 Price Target

Financial news for PRQR dated on 2018-09-18: Stocks Which Set New 52-Week High Yesterday, September 17th

Financial news for PRQR dated on 2018-09-17: 44 Biggest Movers From Friday

Financial news for PRQR dated on 2018-09-13: 48 Biggest Movers From Yesterday

Financial news for PRQR dated on 2018-09-12: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for PRQR dated on 2018-09-12: Stocks Which Set New 52-Week High Yesterday, September 11th

Financial news for PRQR dated on 2018-09-12: The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt

Financial news for PRQR dated on 2018-09-12: 48 Biggest Movers From Yesterday

Financial news for PRQR dated on 2018-09-11: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for PRQR dated on 2018-09-11: The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces \$175M Offering, Leadership Transition At Insulet

Financial news for PRQR dated on 2018-09-11: 51 Biggest Movers From Yesterday

Financial news for PRQR dated on 2018-09-07: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for PRQR dated on 2018-09-07: 55 Biggest Movers From Yesterday

Financial news for PRQR dated on 2018-09-07: ProQR Prices 5.75M Share Underwritten Public Offering of Ordinary Shares @\$15.75/Share

Financial news for PRQR dated on 2018-09-06: 40 Stocks Moving In Thursday's Mid-Day Session

Financial news for PRQR dated on 2018-09-06: Stocks Which Set New 52-Week High Yesterday, September 5th

Financial news for PRQR dated on 2018-09-06: The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data

Financial news for PRQR dated on 2018-09-06: 21 Stocks Moving In Thursday's Pre-Market Session

Financial news for PRQR dated on 2018-09-06: A Peek Into The Markets: US Stock Futures Rise Ahead Of Economic Reports

Financial news for PRQR dated on 2018-09-06: 10 Stocks To Watch For September 6, 2018

Financial news for PRQR dated on 2018-09-06: 54 Biggest Movers From Yesterday

Financial news for PRQR dated on 2018-09-05: ProQR Therapeutics shares are down 88.8% after the company announced a \$75 million offering.

Financial news for PRQR dated on 2018-09-05: 5 Stocks Moving In Wednesday's After-Hours Session

Financial news for PRQR dated on 2018-09-05: Mid-Afternoon Market Update: Crude Oil Down 1.5%; Histogenics Shares Plunge

Financial news for PRQR dated on 2018-09-05: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for PRQR dated on 2018-09-05: Mid-Day Market Update: NASDAQ Down Over 100 Points; ProQR Therapeutics Shares Surge

Financial news for PRQR dated on 2018-09-05: Mid-Morning Market Update: Markets Open Lower; HD Supply Earnings Top Expectations

Financial news for PRQR dated on 2018-09-05: Stocks Which Set New 52-Week High Yesterday, September 4th

Financial news for PRQR dated on 2018-09-05: ProQR Therapeutics shares are up 74.8% premarket after the company announced positive interim results from its Phase 1/2 trial of QR-110 in LCA10 eye disease.

Financial news for PRQR dated on 2018-09-05: Benzinga Pro's 6 Stocks To Watch Today

Financial news for PRQR dated on 2018-09-05: The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results

Financial news for PRQR dated on 2018-09-05: 26 Stocks Moving In Wednesday's Pre-Market Session

Financial news for PRQR dated on 2018-09-02: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Financial news for PRQR dated on 2018-08-15: ProQR To Present Interim Phase 1/2 Results For QR-110 In Leber's Congenital Amaurosis 10 At Symposium for Retinal Degeneration on Sept. 5th

Financial news for PRQR dated on 2018-08-10: Stocks Which Set New 52-Week High Yesterday, August 9th

Financial news for PRQR dated on 2018-08-09: Stocks Which Set New 52-Week High Yesterday, August 8th

Financial news for PRQR dated on 2018-06-28: ProQR Announces the Initiation of a Phase 1/2 Trial for QR-313

Financial news for PRQR dated on 2018-06-12: ProQR Receives Up To \$5 Million In Partnership With EB Research Partnership And EB Medical Research Foundation To Develop QR-313 For Treatment Of Dystrophic Epidermolysis Bullosa

Financial news for PRQR dated on 2018-06-05: 44 Biggest Movers From Yesterday

Financial news for PRQR dated on 2018-05-13: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for PRQR dated on 2018-05-09: ProQR Q1 EPS EUR(0.34) vs EUR(0.45) In Same Qtr. Last Year

Financial news for PRQR dated on 2018-04-23: ProQR Says 8 of 12 Patients Have Been Enrolled in its Phase 1/2 Trial of QR-110, Says On Track to Deliver Data in 2H 2018

Financial news for PRQR dated on 2018-04-05: Benzinga's Top Upgrades, Downgrades For April 5, 2018

Financial news for PRQR dated on 2018-04-05: Chardan Capital Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces \$4.50 Price Target

Financial news for PRQR dated on 2018-02-28: ProQR Reports Q4 EPS EUR(0.39) vs EUR(0.38) In Same Qtr. Last Year

Financial news for PRQR dated on 2018-02-12: Foundation Fighting Blindness will

provide up to \$7.5 million in funding to develop ProQR's candidate QR-421a for Usher syndrome type 2A

Financial news for PRQR dated on 2018-01-08: ProQR, Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR's Axiomer technology

Financial news for PRQR dated on 2017-11-29: ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa

Financial news for PRQR dated on 2017-11-21: ProQR Therapeutics Shares Moving Higher As Traders Pass Link That Suggest Co. Has Received EU Orphan Drug Status For Treatment of Retinitis Pigmentosa

Financial news for PRQR dated on 2017-11-20: ProQR Reports Q3 EPS EUR (0.42)

Financial news for PRQR dated on 2017-11-15: 46 Biggest Movers From Yesterday

Financial news for PRQR dated on 2017-11-14: 42 Stocks Moving In Tuesday's Mid-Day Session

Financial news for PRQR dated on 2017-11-14: ProQR Prices \$20M Offering at \$3.25/Share

Financial news for PRQR dated on 2017-11-13: ProQR Announces Offering Common Stock, No Size Disclosed

Financial news for PRQR dated on 2017-11-13: ProQR Doses First Patient in LCA Trial of QR-110

Financial news for PRQR dated on 2017-09-26: ProQR Therapeutics Shares Sold Off Throughout Tuesday's Trading Session Following 10% After-Hours Move Higher Mon. Amid Data For QR-010 Phase 1b Trial; Stock Down 12+% Tues. Afternoon; Leerink, HC Wainwright Each Made Positive Comments Earlier

Financial news for PRQR dated on 2017-09-26: 15 Biggest Mid-Day Losers For Tuesday

Financial news for PRQR dated on 2017-09-26: What's The Thesis On ProQR Now, After Promising Phase 1 Data?

Financial news for PRQR dated on 2017-09-26: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for PRQR dated on 2017-09-25: ProQR Announces 'Positive' Top-line Data From Phase 1b Study Of QR-010, Clinically Meaningful Improvement In CF Respiratory Systems, Safe And Well-Tolerated

Financial news for PRQR dated on 2017-09-25: REMINDER: ProQR Phase 1b Topline Date Due Today For Translarna

Financial news for PRQR dated on 2017-09-21: 12 Biggest Mid-Day Gainers For Thursday

Financial news for PRQR dated on 2017-09-20: 28 Stocks Moving In Wednesday's Pre-Market Session

Financial news for PRQR dated on 2017-09-19: 10 Biggest Mid-Day Gainers For Tuesday

Financial news for PRQR dated on 2017-09-19: ProQR Recieves Orphan Drug Designation from the FDA for QR-313

Financial news for PRQR dated on 2017-09-12: ProQR Spins out Amylon Therapeutics as a Private Company with Funding from Institutional and Private Investors, Terms Not Disclosed

Financial news for PRQR dated on 2017-09-05: ProQR Therapeutics' QRX-421 Granted Orphan Drug Designation by the FDA and EMA

Financial news for PRQR dated on 2017-08-30: Volume Comes Into ProQR Therapeutics Shares, Stock Spikes ~7% Following Trader Circulation Of Report A Co. Drug May Have Won Orphan Drug Designation In EU

Financial news for PRQR dated on 2017-08-16: ProQR Therapeutics Reports Q2 EUR(0.47) vs EUR(0.43) In Same Qtr. Last Year

Financial news for PRQR dated on 2017-07-05: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for PRQR dated on 2017-07-05: ProQR Announces QR\$X 4-11 For Usher Syndrome Receives Orphan Drug Designation From FDA, EMA

Financial news for PRQR dated on 2017-06-27: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for PRQR dated on 2017-06-15: ProQR to Provide Update on Pipeline; Introduces AxioMer, a Novel Proprietary RNA Technology -

Financial news for PRQR dated on 2017-06-08: ProQR Will Present QR-010 Data At European CF Society Conference, Sees Topline Safety, Exploratory Efficacy Data From Multiple Dose Cohorts In Phase 1B Trial Expected In Sept. 2017

Financial news for PRQR dated on 2017-05-31: ProQR Therapeutics Receives Fast Track Designation for QR-110

Financial news for PRQR dated on 2017-05-17: ProQR Q1 EPS \$(0.45) vs \$(0.52) Est

Financial news for PRQR dated on 2017-04-27: ProQR Therapeutics Reports Clearance of IND App to Begin Clinical Trial for QR-110 in Leber's Congenital Amaurosis Type 10 Patients

Financial news for PRQR dated on 2017-02-28: ProQR Reports Q4 \$(0.38) vs. \$(0.53) Est.

Financial news for PRQR dated on 2016-11-14: ProQR Reports Q3 EPS E\$(0.43) vs. Est. \$(0.55)

Financial news for PRQR dated on 2016-10-27: Mid-Morning Market Update: Markets Open Higher; Twitter Beats Q3 Expectations

Financial news for PRQR dated on 2016-10-27: ProQR Shares Spiking 40%

Financial news for PRQR dated on 2016-10-27: UPDATE: ProQR Therapeutics Presenting Phase 1b Prelim Data At North American Cystic Fibrosis Conference

Financial news for PRQR dated on 2016-10-27: ProQR Therapeutics +28.4% Premarket @ \$7.90; Co Announced QR-010 Met Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients

Financial news for PRQR dated on 2016-10-27: ProQR Therapeutics Shares Up 26% Premarket After Co. Reports QR-010 Meets Primary Endpoint in Study of Homozygous F508del CF Patients

Financial news for PRQR dated on 2016-10-17: 14 Stocks Which Plummeted Three Days On Increasing Volume

Financial news for PRQR dated on 2016-09-29: Janney Capital Initiates Coverage on ProQR Therapeutics at Neutral

Financial news for PRQR dated on 2016-08-17: ProQR Q2 EPS EUR(0.43) vs EUR(0.48) est, Revenue EUR 589K vs EUR 110K est

Financial news for PRQR dated on 2016-07-19: ProQR Reports Received Fast Track Designation for QR-010 for Cystic Fibrosis

Financial news for PRQR dated on 2016-06-20: ProQR Therapeutics Has Limited Downside Or Upside According to Chardan

Financial news for PRQR dated on 2016-06-20: Chardan Capital Initiates Coverage on ProQR Therapeutics at Neutral, Announces \$4.50 PT

Financial news for PRQR dated on 2016-06-01: ProQR's Drug Candidate QR-110 for Leber's Congenital Amaurosis Type 10 Receives EMA, FDA Orphan Drug Designation; Grants 7 Years Market Exclusivity In U.S. And 10 Years In Europe

Financial news for PRQR dated on 2016-05-18: ProQR Q1 EPS EUR (\$0.44) vs EUR (\$0.41) est

Financial news for PRQR dated on 2016-04-11: Prudential Financial Inc Reports 11.5% Passive Stake In Proqr Therapeutics in 13G

Financial news for PRQR dated on 2016-04-08: Jennison Associates Reports 11.5% Passive Stake In Proqr Therapeutics as of March 31, 2016 in 13G-

Financial news for PRQR dated on 2016-03-15: JMP Securities Maintains Market Outperform on ProQR Therapeutics, Lowers PT to \$14.00

Financial news for PRQR dated on 2016-02-17: ProQR Reports Q4 EPS E\$(0.26) vs. Est. E\$(0.39)

Financial news for PRQR dated on 2015-11-23: Mid-Afternoon Market Update: US Stocks

Down; GameStop Shares Dip On Weak Results

Financial news for PRQR dated on 2015-11-23: Mid-Day Market Update: TeleCommunication Systems Surges On Acquisition News; ProQR Therapeutics Shares Slide

Financial news for PRQR dated on 2015-11-23: Mid-Morning Market Update: Markets Mostly Flat; Pfizer To Buy Allergan

Financial news for PRQR dated on 2015-11-23: Morning Market Losers

Financial news for PRQR dated on 2015-11-23: ProQR Says Data Now Expected in Mid to Late 2016, Reports Q3 EPS -\$0.29

Financial news for PRQR dated on 2015-10-06: Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

Financial news for PRQR dated on 2015-09-14: ProQR Announces a Proof-of-Concept Nasal Potential Difference Study of QR-010 is Open for Enrollment

Financial news for PRQR dated on 2015-08-19: ProQR Therapeutics Reports Q2 Loss EURO\$0.37 Vs Est Loss EURO\$0.34

Financial news for PRQR dated on 2015-06-26: ProQR Therapeutics N.V. Begins Enrollment for PQ-010-001 Study

Financial news for PRQR dated on 2015-05-21: ProQR Therapeutics Reports Q1 EPS E\$0.01

Financial news for PRQR dated on 2014-10-15: Benzinga's Top Initiations

Financial news for PRQR dated on 2014-10-15: Deutsche Bank Initiates ProQR Therapeutics With Buy

Financial news for PRQR dated on 2014-10-15: Deutsche Bank Initiates Coverage on ProQR Therapeutics at Buy, Announces \$32.00 PT

Financial news for PRQR dated on 2014-10-14: JMP Securities Initiates Coverage on ProQR Therapeutics at Market Outperform, Announces \$36.00 PT

Financial news for PRQR dated on 2014-10-13: Midday Losers From October 13 - GoPro, Aerohive Networks, Lithia Motors And More

Financial news for PRQR dated on 2014-10-13: Leerink Partners Initiates Coverage on ProQR Therapeutics at Outperform, Announces \$24.00 PT

Financial news for PRQR dated on 2014-10-13: HC Wainwright Initiates Coverage on ProQR Therapeutics at Buy, Announces \$40.00 PT

Financial news for PRQR dated on 2014-10-13: Benzinga's Top Initiations

Financial news for PRQR dated on 2014-10-13: Jefferies Initiates ProQR Therapeutics With Outperform

Financial news for PRQR dated on 2014-10-13: Jefferies Initiates Coverage on ProQR Therapeutics at Outperform, Announces \$24.00 PT

Financial news for PRQR dated on 2014-09-18: Shares of ProQR Therapeutics Open for Trade at \$19.99/Share, IPO Priced at \$13

Financial news for PRQR dated on 2014-09-18: Expected IPOs For Thursday September 18

Financial news for PRQR dated on 2014-09-18: ProQR Therapeutics Prices 7.5M Share IPO at \$13.00/Share

Financial news for PRQR dated on 2014-09-15: The Alibaba IPO & Six Other New Issues For The Week Of September 15

Financial news for PRQR dated on 2014-09-08: ProQR Therapeutics Expects 6.25M Share IPO to Price \$11-\$13/Share